Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$171 Mln
P/E Ratio
5.56
P/B Ratio
1.86
Industry P/E
--
Debt to Equity
0.57
ROE
0.42 %
ROCE
19.57 %
Div. Yield
0 %
Book Value
1.88
EPS
0.62
CFO
$-514.89 Mln
EBITDA
$-1,038.16 Mln
Net Profit
$-1,212.22 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
| 11.80 | 18.40 | 22.66 | -20.70 | 1.72 | -15.19 | -34.91 |
|
BSE Sensex
| -2.43 | 0.54 | -3.62 | 6.02 | 9.68 | 21.97 | 10.37 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Puma Biotechnology (PBYI)
| -29.36 | 2.36 | 39.14 | -70.37 | 17.26 | -57.00 | -79.24 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.18 | 10,372.39 | 21.06 | 23.13 | |
| 32.45 | 12,882.28 | -- | -28.77 | |
| 110.07 | 10,998.29 | 33.53 | 14.16 | |
| 73.45 | 7,759.66 | 34.18 | 19.71 |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used... to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. Address: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024 Read more
Founder, Chairman, President, CEO & Secretary
Mr. Alan H. Auerbach
Founder, Chairman, President, CEO & Secretary
Mr. Alan H. Auerbach
Headquarters
Los Angeles, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Puma Biotechnology Inc (PBYI) stood at $ 213 Mln as on 31-Dec-24
The share price of Puma Biotechnology Inc (PBYI) is $3.41 (NASDAQ) as of 20-Mar-2025 16:00 EDT. Puma Biotechnology Inc (PBYI) has given a return of 1.72% in the last 3 years.
Puma Biotechnology Inc (PBYI) has a market capitalisation of $ 171 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Puma Biotechnology Inc (PBYI) is 5.56 times as on 20-Mar-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Puma Biotechnology Inc (PBYI) and enter the required number of quantities and click on buy to purchase the shares of Puma Biotechnology Inc (PBYI).
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California. Address: 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024
The CEO & director of Mr. Alan H. Auerbach. is Puma Biotechnology Inc (PBYI), and CFO & Sr. VP is Mr. Alan H. Auerbach.
There is no promoter pledging in Puma Biotechnology Inc (PBYI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,168
|
|
|
1,141
|
|
|
1,072
|
|
|
1,045
|
| Puma Biotechnology Inc (PBYI) | Ratios |
|---|---|
|
Return on equity(%)
|
41.6
|
|
Operating margin(%)
|
15.86
|
|
Net Margin(%)
|
13.14
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Puma Biotechnology Inc (PBYI) was $0 Mln.
$-0.04
(
